Hyperfine, Inc. filings document a Nasdaq-listed medical device company built around the Swoop® portable MR brain imaging system and related Optive AI™ software. Its Form 8-K reports cover operating results, business updates, preliminary unaudited financial information, investor presentations, and material definitive agreements, including a senior secured term loan facility used for working capital and general corporate purposes.
Proxy materials describe annual meeting matters, governance procedures, and shareholder voting. The filing record also identifies HYPR Class A common stock registered on Nasdaq and provides capital-structure and corporate-governance disclosures tied to commercialization of portable brain MRI.
Hyperfine, Inc. reported preliminary, unaudited third-quarter 2026 revenue of approximately $6.0 million, up 53% sequentially and 55% year over year. Preliminary revenue for the nine months ended September 30, 2026 was approximately $13.8 million. The company reaffirmed its full-year 2026 revenue outlook of approximately $20 million to $22 million.
Cash and cash equivalents were preliminarily estimated at approximately $37.9 million as of September 30, 2026. Preliminary third-quarter net cash burn, a non-GAAP measure, was $5.6 million, down 29% sequentially; nine-month net cash burn was $22.2 million versus $24.2 million for the comparable 2025 period, down 8%. Hyperfine said quarterly revenue exceeded net cash burn for the first time. It calculates net cash burn as the change in cash and cash equivalents less net financing proceeds. Complete third-quarter results are expected during the November 9, 2026 earnings call; estimates remain subject to closing procedures and may change.
Hyperfine, Inc. (HYPR) disclosed that it received a Nasdaq notice on September 17, 2026 for not meeting the minimum bid price requirement for The Nasdaq Global Market. The company’s Class A common stock closed below $1.00 per share for 30 consecutive business days, triggering noncompliance with Nasdaq Listing Rule 5450(a)(1).
The notice does not immediately affect the listing or trading of the stock, and business operations and SEC reporting continue as before. Hyperfine has an initial 180-day compliance period until March 16, 2027, during which its closing bid must be at least $1.00 for a minimum of 10 consecutive business days to regain compliance.
If the company does not regain compliance by that date, it may seek an additional 180-day period by transferring its listing to The Nasdaq Capital Market and meeting that market’s listing standards other than the bid price, potentially including actions such as a reverse stock split. If compliance is still not achieved, the stock may be delisted, subject to a possible appeal to a Nasdaq Hearings Panel.
Hyperfine, Inc. (HYPR) reported that Chief Operating Officer Thomas Teisseyre sold 7,345 shares of Class A Common Stock on August 24, 2026 at a weighted average price of about $0.854 per share. The company states these sales were made solely to cover tax withholding obligations upon vesting of RSUs granted on March 31, 2025 under a "sell to cover" provision. Following this transaction, Teisseyre directly holds 671,256 shares of Hyperfine Class A Common Stock.
Hyperfine, Inc. (HYPR) reported that its CFO and CAO, Brett Hale, sold 7,345 shares of Class A Common Stock on August 24, 2026, at a weighted average price of $0.854 per share, with individual sale prices ranging from $0.854 to $0.868. According to the company’s disclosure, these sales were effected under a “sell to cover” provision solely to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on March 31, 2025. Following this transaction, Hale directly holds 592,420 shares of Hyperfine Class A Common Stock.
Hyperfine, Inc. reported higher revenue but continued losses for the quarter ended June 30, 2026. Total revenue was $3,904 (thousands), up from $2,696 (thousands) a year earlier, driven by increased Swoop® portable MRI device and service sales and higher average selling prices.
Gross profit improved to $1,980 (thousands), while operating expenses declined modestly to $10,449 (thousands), narrowing the operating loss to $8,469 (thousands). Net loss was $9,298 (thousands), similar to the prior-year quarter, with new interest expense and higher warrant-liability fair-value losses offsetting operating improvements. For the first half of 2026, revenue reached $7,807 (thousands) and net loss was $17,921 (thousands). Hyperfine sold 12 Swoop® systems in the quarter and 22 year-to-date. Cash, cash equivalents and restricted cash increased to $44,764 (thousands), supported by a new $15,000 (thousands) term loan and at-the-market equity sales, though long-term debt rose to $13,235 (thousands). Management expects existing capital and anticipated revenue to fund operations for at least twelve months while acknowledging a need to grow revenue or raise additional financing over the longer term.
Hyperfine, Inc. reported higher revenue and system placements for the second quarter ended June 30, 2026. Revenue was $3.9 million, up 44.8% from $2.7 million a year earlier, alongside 12 commercial Swoop® systems sold versus 8 in 2025. Gross profit rose to $2.0 million with a 50.7% gross margin. Operating expenses totaled $10.4 million, with lower research and development spending, and the company recorded a net loss of $9.3 million, or $0.09 per share, similar to the prior year.
Cash and cash equivalents were $43.5 million as of June 30, 2026, up from $35.1 million at year-end, primarily reflecting financing activities completed during the first half of 2026. Management continues to expect 2026 revenue of approximately $20–$22 million and cash burn of approximately $26–$28 million. Hyperfine also reported CE Mark and UKCA approvals and the European launch of its next-generation Swoop® portable MRI system, plus record U.S. scan volumes.
BlackRock, Inc. reports beneficial ownership of Class A stock of Hyperfine Inc. BlackRock’s reporting business units collectively hold 4,671,587 shares, representing 5.5% of the outstanding Class A stock.
BlackRock has sole voting power over 4,605,420 shares and sole dispositive power over all 4,671,587 shares, with no shared voting or dispositive power. The shares are held on behalf of various clients who may receive dividends or sale proceeds, but no single underlying investor holds more than 5% of Hyperfine’s total outstanding common shares. The filing is signed by a Managing Director of BlackRock and includes a power of attorney and a subsidiary-identification exhibit.
Hyperfine, Inc. director Dan Wolterman received a grant of stock options covering 52,600 shares of Class A common stock. The options have an exercise price of $1.49 per share and expire on June 3, 2036. These options vest at the issuer's next regular annual stockholders meeting, subject to his continued service through that date.
Hyperfine, Inc.’s CFO and CAO Brett Hale reported an open-market sale of 6,047 shares of Class A common stock at a weighted average price of $1.65 per share. According to the disclosure, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units granted on March 31, 2025.
After the transaction, Hale directly holds 599,765 shares of Hyperfine common stock. The filing notes the actual sale prices ranged from $1.63 to $1.715 per share, with detailed breakdowns available on request.
Hyperfine, Inc.’s Chief Operating Officer Thomas Teisseyre reported an open-market sale of 6,047 shares of Class A common stock at a weighted average price of $1.65 per share. According to the disclosure, this sale was executed solely to cover tax withholding obligations tied to the vesting of restricted stock units granted on March 31, 2025 under a sell-to-cover provision. Following the transaction, Teisseyre directly holds 678,601 shares of Hyperfine common stock. The shares involved in the sale traded within a price range of $1.63 to $1.715 per share.